Advertisement
Canada markets close in 1 hour 46 minutes
  • S&P/TSX

    22,073.43
    -195.69 (-0.88%)
     
  • S&P 500

    5,257.30
    -20.21 (-0.38%)
     
  • DOW

    38,384.47
    -301.85 (-0.78%)
     
  • CAD/USD

    0.7325
    -0.0014 (-0.19%)
     
  • CRUDE OIL

    74.22
    -2.77 (-3.60%)
     
  • Bitcoin CAD

    94,557.73
    +2,190.49 (+2.37%)
     
  • CMC Crypto 200

    1,450.15
    -17.79 (-1.21%)
     
  • GOLD FUTURES

    2,369.40
    +23.60 (+1.01%)
     
  • RUSSELL 2000

    2,053.51
    -16.62 (-0.80%)
     
  • 10-Yr Bond

    4.4000
    -0.1140 (-2.53%)
     
  • NASDAQ

    16,736.16
    +1.14 (+0.01%)
     
  • VOLATILITY

    13.70
    +0.78 (+6.04%)
     
  • FTSE

    8,262.75
    -12.63 (-0.15%)
     
  • NIKKEI 225

    38,923.03
    +435.13 (+1.13%)
     
  • CAD/EUR

    0.6727
    -0.0035 (-0.52%)
     

Syndax Announces Participation at the Bank of America Securities 2024 Health Care Conference

WALTHAM, Mass., May 9, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of the Syndax management team will participate in a fireside chat at the Bank of America Securities 2024 Health Care Conference on Thursday, May 16, 2024, at 8:00 a.m. PT/ 11:00 a.m. ET.

A live webcast of the fireside chat can be accessed from the Investor section of the Company's website at www.syndax.com, where a replay of the event will also be available for a limited time.

About Syndax

Syndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include revumenib, a highly selective menin inhibitor, and axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. For more information, please visit. For more information, please visit www.syndax.com or follow the Company on X (formerly Twitter) and LinkedIn.

ADVERTISEMENT

Syndax Contact
Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827

SNDX-G

 

Cision
Cision

View original content:https://www.prnewswire.com/news-releases/syndax-announces-participation-at-the-bank-of-america-securities-2024-health-care-conference-302140895.html

SOURCE Syndax Pharmaceuticals, Inc.